Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 2Immunoblastic Lymphadenopathy 2Subcutaneous panniculitis-like T-cell lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Follicular 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Gemcitabine 3Cyclophosphamide 3romidepsin 2pembrolizumab 2duvelisib 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Biopsy 2Azacitidine 2tazemetostat 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1ruxolitinib 1ixazomib 1ivarmacitinib 1fludarabine 1etoposide phosphate 1cemiplimab 1cabiralizumab 1belinostat 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Specimen Handling 1Salvage Therapy 1Prednisolone 1Photons 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × 10-propargyl-10-deazaaminopterin × 90 days × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡